Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)

BACKGROUND: The identification of four Consensus Molecular Subtypes (CMS1–4) of colorectal cancer forms a new paradigm for the design and evaluation of subtype-directed therapeutic strategies. The most aggressive subtype - CMS4 - has the highest chance of disease recurrence. Novel adjuvant therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Ubink, I., Bloemendal, H. J., Elias, S. G., Brink, M. A., Schwartz, M. P., Holierhoek, Y. C. W., Verheijen, P. M., Boerman, A. W., Mathijssen, R. H. J., de Leng, W. W. J., de Weger, R. A., van Grevenstein, W. M. U., Koopman, M., Lolkema, M. P., Kranenburg, O., Borel Rinkes, I. H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395860/
https://www.ncbi.nlm.nih.gov/pubmed/28424071
http://dx.doi.org/10.1186/s12885-017-3264-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395860/
https://www.ncbi.nlm.nih.gov/pubmed/28424071
http://dx.doi.org/10.1186/s12885-017-3264-y

Ejemplares similares